Skip to main content
. 2020 Mar 16;36(4):243–248. doi: 10.3393/ac.2019.10.16.1

Table 1.

Demographic characteristics of patients with CD in the upper GI tract and other sites

Variable Upper GI CD (n = 24) Other site CD (n = 787) P-value
Age at diagnosis (yr) 27 ± 12 26 ± 10 0.75
Age at operation (yr) 33 ± 11 32 ± 10 0.61
Sex, female : male 3 (12.5) : 21 (87.5) 233 (29.6) : 554 (70.4) 0.07
Duration of disease (mo) 73.6 ± 56.6 69.7 ± 61.1 0.87
Follow-up duration (mo) 147.1 ± 59.7 145.1 ± 69.5 0.88
Body mass index at operation (kg/m2) 17.76 ± 2.27 18.55 ± 3.10 0.11
Hospital stay (day) 36.6 ± 58.4 19.4 ± 16.6 0.001*
Family history of CD, yes 0 (0) 24 (3.0) 0.48
History of smoking 0.035*
 None 10 (41.7) 521 (66.2)
 Ex-smoker 11 (45.8) 191 (24.3)
 Current smoker 3 (12.5) 75 (9.5)
Previous abdominal surgery, yes 11 (45.8) 266 (33.7) 0.45
Previous perianal surgery, yes 15 (62.5) 319 (40.6) 0.036*
History of fistula-in-ano 0.06
 Yes 17 (70.8) 393 (49.9)
 No 7 (29.2) 394 (50.1)
Montreal classification behavior 0.76
 Nonstricturing, nonpenetrating (B1) 2 (8.3) 42 (5.4)
 Stricturing (B2) 10 (41.7) 270 (34.3)
 Penetrating (B3) 12 (50.0) 475 (60.3)
Montreal classification location 0.015*
 Ileocolic (L1) 4 (16.7)a 346 (43.9)
 Colic (L2) 4 (16.7)a 54 (6.9)
 Ileal (L3) 16 (66.7)a 387 (49.2)
Medication
 5-Amino-salicylic acid or no medication 8 (33.3) 339 (43.1) 0.21
 IMM 10 (41.7) 243 (30.9) 0.27
 Anti-TNF-a 1 (4.2) 48 (6.1) 0.57
 Steroid 0 (0) 42 (5.3) 0.63
 IMM+TNF 3 (12.5) 54 (6.9) 0.24
 IMM+steroid 2 (8.3) 41 (5.2) 0.37
 Steroid+TNF 0 (0) 8 (1.0) 0.79
 All combination 0 (0) 12 (1.5) 0.70

Values are presented as mean±standard deviation or number (%).

CD, Crohn disease; GI, gastrointestinal; IMM, immunomodulatory; TNF, tumor necrosis factor.

*

P<0.05, significant differences.

a

This number and proportion included other site Crohn disease with upper gastrointestinal Crohn disease.